期刊
JOURNAL OF CLINICAL GASTROENTEROLOGY
卷 55, 期 9, 页码 757-765出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0000000000001600
关键词
COVID-19; gastroenterology; hepatology; inflammatory bowel disease; endoscopy practice
COVID-19, caused by SARS-CoV-2, affects the gastrointestinal tract in over 40% of infected patients due to the abundance of angiotensin-converting enzyme 2 receptor. Studies show mild liver enzyme elevations in patients with preexisting liver disease and inflammatory bowel disease, with no increased risk from the use of biological agents.
The 2019 coronavirus disease (COVID-19), an airborne infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic. SARS-CoV-2 relies on the angiotensin-converting enzyme 2 receptor for cellular entry and the abundance of this receptor in the gastrointestinal (GI) tract may help explain the GI manifestations, including dysgeusia, nausea, vomiting, diarrhea, and abdominal pain, present in over 40% of infected patients. GI tract involvement also raises the concern for oral-fecal transmission which is poorly understood. Outcome studies in COVID-19 patients with preexisting liver disease and inflammatory bowel disease show predominantly mild transaminase elevations and no increased risk from the use of biological agents in inflammatory bowel disease patients. High-dose corticosteroids, however, should be avoided. As endoscopic procedures are aerosol-generating, modifications to clinical practice is necessary to minimize the spread of COVID-19. We have reviewed current literature to describe the impact of COVID-19 in gastroenterology and hepatology as well as targets of future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据